Phase Ib Study of Atezolizumab Plus Interferon-alpha with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors

This Phase Ib study combined programmed death-ligand 1 inhibitor, atezolizumab, with other immunomodulatory agents in locally advanced and metastatic solid tumors. Arms B-D evaluated atezolizumab plus interferon-alpha, with/without vascular endothelial growth factor inhibitor, bevacizumab, in renal cell carcinoma (RCC) and other solid tumors. Arm B predominantly recruited patients with previously treated RCC or melanoma to receive atezolizumab plus interferon alpha-2b. Arm C investigated atezolizumab plus polyethylene glycol (PEG)-interferon alpha-2a in previously treated RCC. Arm D evaluated atezolizumab plus PEG-interferon alpha-2a and bevacizumab. Primary objectives were safety and tolerability; secondary objectives included clinical activity. Combination therapy was well tolerated, with safety profiles consistent with known risks of individual agents. The most frequent treatment-related toxicities were fatigue, chills, and pyrexia. The objective response rate (ORR) in arm B was 20.0% overall and 17.8% in patients with previously treated checkpoint inhibitor-naive RCC (n = 45). No responses were reported in arm C. The highest ORR in arm D was 46.7% in patients with treatment-naive RCC (n = 15). Data showed preliminary clinical activity and acceptable tolerability of atezolizumab plus interferon alpha-2b in patients with previously treated checkpoint inhibitor-naive RCC and of atezolizumab plus PEG-interferon alpha-2a and bevacizumab in patients with treatment-naive RCC.